| abstract |
FIELD OF THE INVENTION The present invention relates to an improved Mycoplasma hyopneumoniae bacterial vaccine composition, which preferably provides immunity against infection after administration of a single dose. The composition contains inactivated Mycoplasma hyopneumoniae bacterium and adjuvant mixture, which, in combination, provide immunity against Mycoplasma hyopneumoniae infection after a single dose, and trigger an immune response specific to Mycoplasmahyopneumoniae, including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture of acrylic acid polymer, most preferably Carbopolt, and a metabolizable oil such as one or more unsaturated terylene hydrocarbons, preferably squalene and a polyoxyethylene polyoxypropylene block copolymer such as Pluronic. The vaccine composition may optionally contain a preservative, preferably thimerosal and / or EDTA. HE |